Feasibility of Lipid Nanoparticles for Ocular Delivery of Anti-Inflammatory Drugs

REFERENCES

• Hornof M, Toropainen E, Urtti A. Cell culture models of the ocular barriers. Eur J Pharm Biopharm. 2005;60:207–225.
   PubMed Web of Science ®Google Scholar
• Kaur IP, Kanwar M. Ocular preparations: The formulation approach. Drug Dev Ind Pharm. 2002;28:473–493.
   PubMed Web of Science ®Google Scholar
• Ali Y, Lehmussaari K. Industrial perspective in ocular drug delivery. Adv Drug Deliv Rev. 2006;58:1258–1268.
   PubMed Web of Science ®Google Scholar
• Barar J, Javadzadeh AR, Omidi Y. Ocular novel drug delivery: Impacts of membranes and barriers. Expert Opin Drug Deliv. 2008;5:567–581.
   PubMed Web of Science ®Google Scholar
• Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58:1131–1135.
   PubMed Web of Science ®Google Scholar
• Hughes PM, Olejnik O, Chang-Lin J-E et, al. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev. 2005;57:2010–2032.
   PubMed Web of Science ®Google Scholar
• Kim SH, Lutz RJ, Wang NS, et al. Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res. 2007;39:244–254.
   PubMed Web of Science ®Google Scholar
• Ebrahim S, Peyman GA, Lee PJ. Applications of liposomes in ophthalmology. Surv Ophthalmol. 2005;50:167–182.
   PubMed Web of Science ®Google Scholar
• Kaur IP, Garg A, Singla AK, et al. Vesicular systems in ocular drug delivery: An overview. Int J Pharm. 2004;269:1–14.
   PubMed Web of Science ®Google Scholar
• Ammar HO, Salama HA, Ghorab M, et al. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS Pharm Sci Tech. 2009;10:808–819.
   Google Scholar
• Calvo P, Vila-Jato JL, Alonso MJ. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. J Pharm Sci. 1996;85:530–536.
   PubMed Web of Science ®Google Scholar
• Gaudana R, Jwala J, Boddu SH, et al. Recent perspectives in ocular drug delivery. Pharm Res. 2009;26:1197–1216.
   PubMed Web of Science ®Google Scholar
• Kapoor Y, Chauhan A. Ophthalmic delivery of Cyclosporine A from Brij-97 microemulsion and surfactant-laden p-HEMA hydrogels. Int J Pharm. 2008;361:222–229.
   PubMed Web of Science ®Google Scholar
• Vandamme TF. Microemulsions as ocular drug delivery systems: Recent developments and future challenges. Prog Retin Eye Res. 2002;21:15–34.
   PubMed Web of Science ®Google Scholar
• Le Bourlais C, Acar L, Zia H, et al. Ophthalmic drug delivery systems—Recent advances. Prog Retin Eye Res. 1998;17:33–58.
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Vega E, García ML, et al. Polymeric nanoparticles as drug carriers and cotrolled release implant devices. In: VP Torchilin (Ed.). Nanoparticulates as Drug Carriers. London: Imperial College Press, 2006; pp. 29–42.
   Google Scholar
• Cheng Y, Xu Z, Ma M, et al. Dendrimers as drug carriers: Applications in different routes of drug administration. J Pharm Sci. 2008;97:123–143.
   PubMed Web of Science ®Google Scholar
• Vandamme TF, Brobeck L. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release. 2005;102:23–38.
   PubMed Web of Science ®Google Scholar
• Marano RJ, Toth I, Wimmer N, et al. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: A long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther. 2005;12:1544–1550.
   PubMed Web of Science ®Google Scholar
• Cavalli R, Gasco MR, Chetoni P, et al. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm. 2002;238:241–245.
   PubMed Web of Science ®Google Scholar
• del Pozo-Rodriguez A, Delgado D, Solinis MA, et al. Solid lipid nanoparticles: Formulation factors affecting cell transfection capacity. Int J Pharm. 2007;339:261–268.
   PubMed Web of Science ®Google Scholar
• del Pozo-Rodriguez A, Delgado D, Solinís MA, et al. Solid lipid nanoparticles for retinal gene therapy: Transfection and intracellular trafficking in RPE cells. Int J Pharm. 2008;360:177–183.
   PubMed Web of Science ®Google Scholar
• Attama AA, Reichl S, Muller-Goymann CC. Diclofenac sodium delivery to the eye: In vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm. 2008;355:307–313.
   PubMed Web of Science ®Google Scholar
• Li X, Nie SF, Kong J, et al. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm. 2008;363:177–182.
   PubMed Web of Science ®Google Scholar
• Gokce EH, Sandri G, Bonferoni MC, et al. Cyclosporine A loaded SLNs: Evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm. 2008;364:76–86.
   PubMed Web of Science ®Google Scholar
• Niu M, Shi K, Sun Y, et al. Preparation of CyA-loaded solid lipid nanoparticles and application on ocular preparations. J Drug Deliv Sci Technol. 2008;18:293–297.
   Web of Science ®Google Scholar
• El-Harazi SM, Feldman RM. Control of intra-ocular inflammation associated with cataract surgery. Curr Opin Ophthalmol. 2001;12:4–8.
   PubMed Web of Science ®Google Scholar
• Sunaric-Megevand G, Pournaras CJ. Current approach to postoperative endophthalmitis. Br J Ophthalmol. 1997;81:1006–1015.
   PubMed Web of Science ®Google Scholar
• O’Brien TP. Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care. Curr Med Res Opin. 2005;21:1131–1137.
   PubMed Web of Science ®Google Scholar
• Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica. 2003;217:89–98.
   PubMed Web of Science ®Google Scholar
• Korenfeld M. Difluprednate: Changing the landscape of ocular pharmacology. Expert Rev Ophthalmol. 2008;3:619–625.
   Google Scholar
• Noecker RJ, Golightly SF. Pharmacology in ocular surgery. J Ophthalmic Nurs Technol. 1999;18:101–108.
   PubMedGoogle Scholar
• Ahuja M, Dhake A, Sharma S, et al. Topical ocular delivery of NSAIDs. AAPS J. 2008;10:229–241.
   PubMed Web of Science ®Google Scholar
• Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin. 2002;42:1–11.
   PubMedGoogle Scholar
• Heier JS, Topping TM, Baumann W et al. Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology. 2000;107:2034–2038.
   PubMed Web of Science ®Google Scholar
• Raizman M.Corticosteroid therapy of eye disease. Fifty years later. Arch Ophthalmol. 1996;114:1000–1001.
   PubMed Web of Science ®Google Scholar
• Gaynes BI, Fiscella R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: A safety review. Drug Safety. 2002;25:233–250.
   PubMed Web of Science ®Google Scholar
• Pignatello R, Bucolo C, Ferrara P, et al. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci. 2002;16:53–61.
   PubMed Web of Science ®Google Scholar
• Pignatello R, Bucolo C, Spedalieri G, et al. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials. 2002;23:3247–3255.
   PubMed Web of Science ®Google Scholar
• Vega E, Gamisans F, Garcia ML, et al. PLGA nanospheres for the ocular delivery of flurbiprofen: Drug release and interactions. J Pharm Sci. 2008;97:5306–5317.
   PubMed Web of Science ®Google Scholar
• Vega E, Egea MA, Valls O, et al. Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration. J Pharm Sci. 2006;95:2393–2405.
   PubMed Web of Science ®Google Scholar
• Sashmal S, Mukherjee S, Ray S, et al. Design and optimization of NSAID loaded nanoparticles. Pak J Pharm Sci. 2007;20:157–162.
   PubMed Web of Science ®Google Scholar
• Ghate D, Edelhauser HF. Barriers to glaucoma drug delivery. J Glaucoma. 2008;17:147–156.
   PubMed Web of Science ®Google Scholar
• Watsky MA, McDermott ML, Edelhauser HF. In vitro corneal endothelial permeability in rabbit and human: The effects of age, cataract surgery and diabetes. Exp Eye Res. 1989;49:751–767.
   PubMed Web of Science ®Google Scholar
• Wang W, Sasaki H, Chien DS, et al. Lipophilicity influence on conjunctival drug penetration in the pigmented rabbit: A comparison with corneal penetration. Curr Eye Res. 1991;10:571–579.
   PubMed Web of Science ®Google Scholar
• Bucolo C, Maltese A, Drago F. When nanotechnology meets the ocular surface. Expert Rev Ophthalmol. 2008;3:325–332.
   Google Scholar
• Behar-Cohen FF, BenEzra D, Einmahl S. Challenges of intraocular drug delivery. Eur Pharm Rev. 2001;6:35–40.
   Google Scholar
• Velez G, Whitcup SM. New developments in sustained release drug delivery for the treatment of intraocular disease. Br J Ophthalmol. 1999;83:1225–1229.
   PubMed Web of Science ®Google Scholar
• Liu DT, Lee VY, Lam PT, et al. Acyclovir-induced nephrotoxicity in a patient with acute retinal necrosis. Hong Kong Med. J 2007;13:155–156.
   PubMedGoogle Scholar
• Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci. 2000;41:961–964.
   PubMed Web of Science ®Google Scholar
• Unger WG. Review: Mediation of the ocular response to injury. J Ocul Pharmacol. 1990;6:337–353.
   PubMedGoogle Scholar
• Jaanus SD, Lesher GA.Anti-inflammatory drugs. In: JD Bartlett (Ed.). Clinical Ocular Pharmacology. Oxford: Butterworth-Heineman, 1995; pp. 303–314.
   Google Scholar
• Campbell WB, Halushka PV.Lipid derived autocoids. In: LE Hardman. Goodman and Gilman’s. The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill, 1990; pp. 601–633.
   Google Scholar
• Gaudio P. A review of evidence guiding the use of corticosteroids in the treatment of intraocular inflammation. Ocular Immunol Inflamm. 2004;12:169–192.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Ben-Nun J, Guo H, et al. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000;107:2024–2033.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Pearson PA, Ashton P. Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina. 2000;20:402–403.
   PubMed Web of Science ®Google Scholar
• Samudre SS, Lattanzio FA, Jr Williams, PB, et al. Comparison of topical steroids for acute anterior uveitis. J Ocul Pharmacol Ther. 2004;20:533–547.
   PubMed Web of Science ®Google Scholar
• Recasens JF, Green K. Effects of endotoxin and anti-inflammatory agents on superoxide dismutase in the rabbit iris. Ophthalmic Res. 1990;22:12–18.
   PubMed Web of Science ®Google Scholar
• Bron A, Denis P, Hoang Xuan TC, et al. The effects of Rimexolone 1% in postoperative inflammation after cataract extraction. A double-masked placebo-controlled study, Eur J Ophthalmol. 1998;8:16–21.
   Google Scholar
• Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004;137:337–342.
   PubMed Web of Science ®Google Scholar
• Nagelhout TJ, Gamache DA, Roberts L, et al. Preservation of tear film integrity and inhibition of corneal injury by dexamethasone in a rabbit model of lacrimal gland inflammation-induced dry eye. J Ocul Pharmacol Ther. 2005;21:139–148.
   PubMed Web of Science ®Google Scholar
• Yang CQ, Sun W, Gu YS. A clinical study of the efficacy of topical corticosteroids on dry eye. J Zhejiang Univ Sci B. 2006;7:675–678.
   PubMedGoogle Scholar
• Ferguson VM, Spalton DJ. Recovery of the blood-aqueous barrier after cataract surgery. Br J Ophthalmol. 1991;75:106–110.
   PubMed Web of Science ®Google Scholar
• Jonas JB, Kreissig I, Degenring RF. Cataract surgery after intravitreal injection of triamcinolone acetonide. Eye. 2004;18:361–364.
   PubMed Web of Science ®Google Scholar
• Young S, Larkin G, Branley M, et al. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol. 2001;29:2–6.
   PubMed Web of Science ®Google Scholar
• Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin. 1992;10:505–512.
   PubMed Web of Science ®Google Scholar
• Reddy MS, Suneetha N, Thomas RK, et al. Topical diclofenac sodium for treatment of postoperative inflammation in cataract surgery. Indian J Ophthalmol. 2000;48:223–226.
   PubMedGoogle Scholar
• Leonardi A, Borghesan F, Faggian D, et al. Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. Am J Ophthalmol. 2000;129:151–158.
   PubMed Web of Science ®Google Scholar
• Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol. 2002;47(Suppl.1):203–218.
   Google Scholar
• Price MO, Price FW.Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery. Curr Med Res Opin. 2004;20:2015–2019.
   PubMed Web of Science ®Google Scholar
• Bandare BM, Sankaridurg PR, Willcox MD. Non-steroidal antinflammatory agents decrease bacterial colonization of contact lenses and prevent adhesion to human corneal epithelial cells. Curr Eye Res. 2004;29:245–251.
   PubMed Web of Science ®Google Scholar
• Aragona P, Stilo A, Ferreri F, et al. Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjogren’s syndrome patients. Eye. 2005;19:535–539.
   PubMed Web of Science ®Google Scholar
• Walters T, Raizman M, Ernest P, et al. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007;33:1539–1545.
   PubMed Web of Science ®Google Scholar
• Acosta MC, Luna C, Graff G, et al. Comparative effects of the nonsteroidal anti-inflammatory drug nepafenac on corneal sensory nerve fibers responding to chemical irritation. Invest Ophthalmol Vis Sci. 2007;48:182–188.
   PubMed Web of Science ®Google Scholar
• Thaller VT, Kulshrestha MK, Bell K. The effect of pre-operative topical flurbiprofen or diclofenac on pupil dilatation. Eye. 2000;14:642–645.
   PubMed Web of Science ®Google Scholar
• Gulkilik G, Kocabora S, Taskapili M, et al. Cystoid macular edema after phacoemulsification: Risk factors and effect on visual acuity. Can J Ophthalmol. 2006;41:699–703.
   PubMed Web of Science ®Google Scholar
• Benezra D. The role of cyclosporin eye drops in ocular inflammatory diseases. Ocul Immunol Inflamm. 1993;1:159–162.
   PubMedGoogle Scholar
• Alzamora-Barrios B, Guerra L, Jiménez H, et al. Treatment of severe queratitis sicca and ocular inflammation with cyclosporine A therapy. Rev Soc Peru Med Interna. 2007;20:145–148.
   Google Scholar
• Schechter BA. Ketorolac during the induction phase of cyclosporin-A therapy. J Ocul Pharmacol Ther. 2006;22:150–154.
   PubMed Web of Science ®Google Scholar
• Mohan N, Gupta V, Tandon R, et al. Topical ciprofloxacin-dexamethasone combination therapy after cataract surgery—Randomized controlled clinical trial. J Cataract Refract Surg. 2001;27:1975–1978.
   PubMed Web of Science ®Google Scholar
• Gasco MR, Saettone MF, Zara GP. Pharmaceutical compositions suitable for the treatment of ophthalmic diseases. US Patent Application 2006/0024374; 2006.
   Google Scholar
• Huang ZR, Hua SC, Yang YL, et al. Development and evaluation of lipid nanoparticles for camptothecin delivery: A comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta Pharmacol Sin. 2008;29:1094–1102.
   PubMed Web of Science ®Google Scholar
• Olbrich C, Scholer N, Tabatt K, et al. Cytotoxicity studies of Dynasan 114 solid lipid nanoparticles (SLN) on RAW 264.7 macrophages-impact of phagocytosis on viability and cytokine production. J Pharm Pharmacol. 2004;56:883–891.
   PubMed Web of Science ®Google Scholar
• Shah KA, Joshi MD, Patravale VB. Biocompatible microemulsions for fabrication of glyceryl monostearate solid lipid nanoparticles (SLN) of tretinoin. Journal of Biomedical Nanotechnology. 2009;5:396–400.
   PubMed Web of Science ®Google Scholar
• Caboi F, Lazzari P, Pani L, et al. Effect of 1-butanol on the microstructure of lecithin/water/tripalmitin system. Chem Phys Lipids. 2005;135:147–156.
   PubMed Web of Science ®Google Scholar
• Bunjes H, Koch MHJ, Westesen K. Influence of emulsifiers on the crystallization of solid lipid nanoparticles. J Pharm Sci. 2003;92:1509–1520.
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—A review of the state of the art. Eur J Pharm Biopharm. 2000;50:161–177.
   PubMed Web of Science ®Google Scholar
• Souto EB, Müller RH. Lipid nanoparticles (solid lipid nanoparticles and nanostructured lipid carriers) for cosmetic, dermal and transdermal applications. In: D Thassu, M Deleers, Y Pathak (Eds.). Nanoparticulate Drug Delivery Systems: Recent Trends and Emerging Technologies. Boca Raton, FL: CRC Press, 2007; pp. 213–233.
   Google Scholar
• Souto EB, Müller RH. Lipid nanoparticles (SLN and NLC) for drug delivery. In: AJ Domb, Y Tabata, MNV Ravi Kumar, and S Farber (Eds.). Nanoparticles for Pharmaceutical Applications. Stevenson Ranch, CA: American Scientific Publishers, 2007; pp. 103–122.
   Google Scholar
• Date AA, Joshi MD, Patravale VB. Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev. 2007;59:505–521.
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165–196.
   PubMed Web of Science ®Google Scholar
• Jenning V, Gohla SH. Encapsulation of retinoids in solid lipid nanoparticles (SLN). J Microencapsul. 2001;18:149–158.
   PubMed Web of Science ®Google Scholar
• Goppert TM, Muller RH. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns. J Drug Target. 2005;13:179–187.
   PubMed Web of Science ®Google Scholar
• Joshi M, Patravale V. Formulation and evaluation of nanostructured lipid carrier (NLC)-based gel of Valdecoxib. Drug Dev Ind Pharm. 2006;32:911–918.
   PubMed Web of Science ®Google Scholar
• Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002;242:121–128.
   PubMed Web of Science ®Google Scholar
• Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54:S131–S155.
   PubMed Web of Science ®Google Scholar
• Hu FQ, Jiang SP, Du YZ, et al. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B Biointerfaces. 2005;45:167–173.
   PubMed Web of Science ®Google Scholar
• Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: A literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87:1479–1488.
   PubMed Web of Science ®Google Scholar
• Qaddoumi MG, Ueda H, Yang J, et al. The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm Res. 2004;21:641–648.
   PubMed Web of Science ®Google Scholar
• Bu H-Z Gukasyan, HJ, Goulet L, et al. Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. Curr Drug Metab. 2007;8:91–107.
   PubMedGoogle Scholar
• Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008;13:144–151.
   PubMed Web of Science ®Google Scholar
• Pardeike J, Hommoss A, Muller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366:170–184.
   PubMed Web of Science ®Google Scholar
• González-Mira E, Marquez A, Egea MA, et al. Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. Colloid Surf B Biointer. 2010, (submitted).
   PubMedGoogle Scholar
• Müller-Goymann CC. Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur J Pharm Biopharm. 2004;58:343–356.
   PubMed Web of Science ®Google Scholar
• Sandri G, Bonferoni MC, Gökçe EH, et al. Chitosan associated solid lipid nanoparticles: Assessment of penetration enhancement properties using RCE cell line. In: 36th Controlled Release Society Annual Meeting & Exposition, Copenhagen, Denmark, July 18–23, 2009.
   Google Scholar
• Shen J, Wang Y, Ping Q, et al. Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery. J Control Release. 2009;137:217–223.
   PubMed Web of Science ®Google Scholar
• Basaran E, Demirel M, Sirmagul B, et al. Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J Microencapsul. 2010;27:37–47.
   PubMedGoogle Scholar
• Araujo J, Gonzalez E, Egea MA, et al. Nanomedicines for ocular NSAIDs: Safety on drug delivery. Nanomedicine. 2009;5:394–401.
   Google Scholar
• Attama AA, Reichl S, Muller-Goymann CC. Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea. Current Eye Res. 2009;34:698–705.
   PubMed Web of Science ®Google Scholar
• del Pozo-Rodriguez A, Solinís MA, Gascón AR, et al. Short- and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy. Eur J Pharm Biopharm. 2009;71:181–189.
   PubMed Web of Science ®Google Scholar
• Li VHK, Wood RW, Kreuter J, et al. Ocular drug delivery of progesterone using nanoparticles. J Microencapul. 1986;3:213–218.
   PubMedGoogle Scholar
• Xu J, Wang Y, Yue Li Y, et al. Inhibitory efficacy of intravitreal dexamethasone acetate-loaded PLGA nanoparticles on choroidal neovascularization in a laser-induced rat model. J Ocul Pharmacol Ther. 2007;23:527–540.
   PubMed Web of Science ®Google Scholar
• Valls R, Vega E, Garcia ML, et al. Transcorneal permeation in a corneal device of non-steroidal anti-inflammatory drugs in drug delivery systems. Open Med Chem J. 2008;2:66–71.
   PubMedGoogle Scholar
• Michalowski CB, Guterres SS, Dalla Costa T. Microdialysis for evaluating the entrapment and release of a lipophilic drug from nanoparticles. J Pharm Biomed Anal. 2004;35:1093–1100.
   PubMed Web of Science ®Google Scholar
• Agnihotri SM, Vavia PR. Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. Nanomedicine. 2009;5:90–95.
   PubMed Web of Science ®Google Scholar
• Solomon KD, Cheetham JK, DeGryse R, et al. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. Ophthalmology. 2001;108:331–337.
   PubMed Web of Science ®Google Scholar
• Lekhanont K, Park CY, Smith JA, et al. Effects of topical anti-inflammatory agents in a botulinum toxin B-induced mouse model of keratoconjunctivitis sicca. J Ocul Pharmacol Ther. 2007;23:27–34.
   PubMedGoogle Scholar
• Lindstrom R, Holland E, Lane S, et al. Double-masked comparison of ketorolac tromethamine 0.4% versus nepafenac sodium 0.1% for postoperative healing rates and pain control in eyes undergoing surface ablation. Cornea. 2008;27:385–386; author reply 386–387.
   PubMedGoogle Scholar
• Lindstrom R, Kim T. Ocular permeation and inhibition of retinal inflammation: An examination of data and expert opinion on the clinical utility of nepafenac. Curr Med Res Opin. 2006;22:397–404.
   PubMed Web of Science ®Google Scholar
• Samati Y, Yuksel N, Tarimci N. Preparation and characterization of poly(D,L-lactic-co-glycolic acid) microspheres containing flurbiprofen sodium. Drug Deliv. 2006;13:105–111.
   PubMed Web of Science ®Google Scholar
• Coimbra PA, De Sousa HC, Gil MH. Preparation and characterization of flurbiprofen-loaded poly(3-hydroxybutyrate-co-3-hydroxyvalerate) microspheres. J Microencapsul. 2008;25:170–178.
   PubMed Web of Science ®Google Scholar
• Gamisans F, Lacoulonche F, Chauvet A, et al. Flurbiprofen-loaded nanospheres: Analysis of the matrix structure by thermal methods. Int J Pharm. 1999;179:37–48.
   PubMed Web of Science ®Google Scholar
• Ward DA. Comparative efficacy of topically applied flurbiprofen, diclofenac, tolmetin, and suprofen for the treatment of experimentally induced blood-aqueous barrier disruption in dogs. Am J Vet Res. 1996;57:875–878.
   PubMedGoogle Scholar
• González E, Ricart D, Egea MA, et al. Polyester nanospheres as ocular ibuprofen drug delivery system. In 7th Conference and Workshop on Biological Barriers and Nanomedicine Advanced Drug Delivery and Predictive non vivo Testing Technologies; Saarbrucken, Germany, February 20-29th, 2008.
   Google Scholar
• Hasan AS, Socha M, Lamprecht A, et al. Effect of the microencapsulation of nanoparticles on the reduction of burst release. Int J Pharm. 2007;344:53–61.
   PubMed Web of Science ®Google Scholar
• Ogawa T, Ohara K, Shimizu H.Effects of pretreatment with mydriatics on intraocular penetration of 0.1% pranoprofen. Jpn J Ophthalmol. 1993;37:47–55.
   PubMedGoogle Scholar
• Yavas GF, Ozturk F, Kusbeci T. Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema. J Cataract Refract Surg. 2007;33:804–807.
   PubMed Web of Science ®Google Scholar
• Calvo P, Vila-Jato JL, Alonso MJ. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. J Pharm Sci 2000;85:530–536.
   Google Scholar
• Calvo P, Vila-Jato JL, Alonso MJ. Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. Int J Pharm. 1997;153:41–50.
   Web of Science ®Google Scholar
• Badawi AA, El-Laithy HM, El Qidra RK, et al. Chitosan based nanocarriers for indomethacin ocular delivery. Arch Pharm Res. 2008;31:1040–1049.
   PubMed Web of Science ®Google Scholar